// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,989
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,989 results Live
FDA Devatis May 22 — 0.00

FDA Approves LENALIDOMIDE — Devatis Inc.

Devatis Inc. secured FDA approval for its oral Lenalidomide generic, positioning the manufacturer to capture potential market share in the myeloma treatment space amidst anticipate…

FDA BRISTOL Apr 17 — 0.00

FDA Approves Unknown Drug — BRISTOL

On April 17, 2025, Bristol received approval for a new drug application (NDA 220073), a development that is poised to reshape the competitive landscape for the specified therapeuti…

FDA Camber Apr 14 — 0.00

FDA Approves IMATINIB MESYLATE — Camber Pharmaceuticals, Inc.

# FDA Approves Generic Imatinib Mesylate Camber Pharmaceuticals, Inc. has received FDA approval for its generic formulation of imatinib mesylate, an oral tyrosine kinase inhibitor…

FDA Fresenius Mar 14 — 0.00

FDA Approves TYENNE — Fresenius Kabi USA, LLC

Fresenius Kabi USA announced on March 14, 2025, the FDA approval of its biosimilar TOCILIZUMAB (TYENNE), a fully human monoclonal antibody for injection. This approval introduces a…

FDA Scienture Mar 13 — 0.00

FDA Approves ARBLI — Scienture LLC

# FDA Approves Scienture LLC's ARBLI (Losartan Potassium) for Oral Use The U.S. Food and Drug Administration has approved Scienture LLC's ARBLI (losartan potassium) oral formulati…

FDA BIOCON Mar 3 — 0.00

FDA Approves LENALIDOMIDE — BIOCON PHARMA INC.,

# FDA Approves BIOCON PHARMA's Generic Lenalidomide, Expanding Access to Key Multiple Myeloma Treatment BIOCON PHARMA INC. has received FDA approval for its generic lenalidomide o…

FDA Lupin Feb 5 — 0.00

FDA Approves BOSENTAN — Lupin Pharmaceuticals, Inc.

# FDA Approves Generic Bosentan; Lupin Pharmaceuticals Enters Pulmonary Hypertension Market Lupin Pharmaceuticals, Inc. has received FDA approval for generic bosentan oral tablets…

FDA MDD Feb 3 — 0.00

FDA Approves ONAPGO — MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc

Supernus Pharmaceuticals, Inc. announced the FDA approval of ONAPGO (apomorphine hydrochloride) for subcutaneous administration, a launch expected to bolster its market share and d…

FDA Macleods Jan 31 — 0.00

FDA Approves TRAMADOL HYDROCHLORIDE — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited obtained FDA approval for its generic Tramadol Hydrochloride oral tablets (ANDA209404), a milestone likely to drive revenue growth and strengthen i…

FDA Rising Jan 23 — 0.00

FDA Approves SPIRONOLACTONE — Rising Pharma Holdings, Inc.

Rising Pharma Holdings, Inc. received FDA approval Monday to market its generic version of the antihypertensive and diuretic Spirionolactone (ANDA219494), potentially broadening ac…

FDA Daiichi Jan 17 — 0.00

FDA Approves DATROWAY — Daiichi Sankyo Inc.

# FDA Approves Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) for Oncology Treatment Daiichi Sankyo Inc. received FDA approval for DATROWAY (datopotamab deruxtecan), an intrav…

FDA YICHANG Jan 16 — 0.00

FDA Approves Unknown Drug — YICHANG HUMANWELL

Yichang Humanwell announced the FDA’s approval of NDA ANDA219072 on January 16, setting the stage for a new market entrant and driving shareholder value amidst the intensifying gen…

FDA E.R. Dec 27 — 0.00

FDA Approves OPDIVO QVANTIG — E.R. Squibb & Sons, L.L.C.

On December 27, 2024, the FDA approved **E.R. Squibb & Sons, L.L.C.**’s OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy), a novel subcutaneous formulation of its flagship immunoth…

FDA AUROBINDO Dec 26 — 0.00

FDA Approves Unknown Drug — AUROBINDO PHARMA LTD

# FDA Approves Generic Drug Application for Aurobindo Pharma Aurobindo Pharma Ltd. received FDA approval for ANDA215971 on December 26, 2024, expanding its generic pharmaceutical …

FDA Merus Dec 4 — 0.00

FDA Approves BIZENGRI — Merus US, Inc.

The FDA’s approval of Zenocutuzumab (Bizengri) on December 4 grants Merus US, Inc. commercial rights to a first-in-class therapy for NRG1 fusion-positive cancers, positioning the c…

FDA Biocon Nov 29 — 0.00

FDA Approves YESINTEK — Biocon Biologics Inc.

Biocon Biologics Inc. announced the FDA approval of YESINTEK (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis, a strategic expansion into the lucrative autoim…

FDA Wuxi Nov 7 — 0.00

FDA Approves MYCOPHENOLATE MOFETIL — Wuxi Fortune Pharmaceutical Co.,Ltd.

Wuxi Fortune Pharmaceutical has secured FDA approval for its generic Mycophenolate Mofetil (ANDA 214079), signals an escalation in its U.S. market presence. The approval will likel…

FDA Azurity Nov 7 — 0.00

FDA Approves DANZITEN — Azurity Pharmaceuticals, Inc.

On November 7, 2024, Azurity Pharmaceuticals received FDA approval for Danziten (nilotinib), expanding access to this oral therapy amid a competitive climate for chronic myeloid le…

FDA UBI Oct 17 — 0.00

FDA Approves LEUPROLIDE ACETATE — UBI Pharma Inc.

# FDA Approves UBI Pharma's Generic Leuprolide Acetate Injection The FDA has approved UBI Pharma Inc.'s abbreviated new drug application (ANDA) for leuprolide acetate subcutaneous…

FDA AbbVie Oct 16 — 0.00

FDA Approves VYALEV — AbbVie Inc.

# FDA Approves AbbVie's VYALEV for Parkinson's Disease Treatment AbbVie Inc. received FDA approval for VYALEV (foscarbidopa/foslevodopa) subcutaneous injection, a novel formulatio…